0001209191-18-054716.txt : 20181010 0001209191-18-054716.hdr.sgml : 20181010 20181010180257 ACCESSION NUMBER: 0001209191-18-054716 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181008 FILED AS OF DATE: 20181010 DATE AS OF CHANGE: 20181010 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vaughn James J CENTRAL INDEX KEY: 0001649689 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51541 FILM NUMBER: 181116825 MAIL ADDRESS: STREET 1: C/O GENOMIC HEALTH, INC. STREET 2: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-10-08 0 0001131324 GENOMIC HEALTH INC GHDX 0001649689 Vaughn James J 301 PENOBSCOT DRIVE REDWOOD CITY CA 94063 0 1 0 0 Chief Commercial Officer Common Stock 2018-10-08 4 M 0 3732 28.05 A 21274 D Common Stock 2018-10-08 4 M 0 18110 30.84 A 39384 D Common Stock 2018-10-08 4 M 0 2838 31.12 A 42222 D Common Stock 2018-10-08 4 M 0 320 27.00 A 42542 D Common Stock 2018-10-08 4 S 0 16215 64.976 D 26327 D Common Stock 2018-10-08 4 S 0 6310 65.8155 D 20017 D Common Stock 2018-10-08 4 S 0 2475 66.5197 D 17542 D Common Stock 2018-10-09 4 M 0 5653 27.48 A 23195 D Common Stock 2018-10-09 4 M 0 2390 31.12 A 25585 D Common Stock 2018-10-09 4 M 0 16957 27.00 A 42542 D Common Stock 2018-10-09 4 S 0 19270 64.2293 D 23272 D Common Stock 2018-10-09 4 S 0 5730 64.8563 D 17542 D Employee Stock Option (right to buy) 28.05 2018-10-08 4 M 0 3732 0.00 D 2023-01-31 Common Stock 3732 0 D Employee Stock Option (right to buy) 30.84 2018-10-08 4 M 0 18110 0.00 D 2024-01-28 Common Stock 18110 0 D Employee Stock Option (right to buy) Holding 31.12 2018-10-08 4 M 0 2838 0.00 D 2025-02-13 Common Stock 2838 42162 D Employee Stock Option (right to buy) Holding 31.12 2018-10-09 4 M 0 2390 0.00 D 2025-02-13 Common Stock 2390 39772 D Employee Stock Option (right to buy) Holding 27.00 2018-10-08 4 M 0 320 0.00 D 2026-02-16 Common Stock 320 41380 D Employee Stock Option (right to buy) Holding 27.00 2018-10-09 4 M 0 16957 0.00 D 2026-02-16 Common Stock 16957 24423 D Employee Stock Option (right to buy) Holding 27.48 2018-10-09 4 M 0 5653 0.00 D 2027-01-31 Common Stock 5653 34927 D Includes an aggregate of 15,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 6, 2018. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Represents weighted average sale price. Actual sale prices ranged from $64.37 to $65.34. Represents weighted average sale price. Actual sale prices ranged from $65.37 to $66.36. Represents weighted average sale price. Actual sale prices ranged from $66.37 to $66.76. Represents weighted average sale price. Actual sale prices ranged from $63.57 to $64.56. Represents weighted average sale price. Actual sale prices ranged from $64.57 to $65.27. The option became exercisable as to 25% of the shares on January 31, 2014, and became exercisable as to 1/48th of the shares each full month thereafter. The option became exercisable as to 25% of the shares on January 28, 2015, and became exercisable as to 1/48th of the shares each full month thereafter. The option becomes exercisable as to 25% of the shares on February 13, 2016, and becomes exercisable as to 1/48th of the shares each full month thereafter. The option became exercisable as to 25% of the shares on February 16, 2017, and becomes exercisable as to 1/48th of the shares each full month thereafter. The option became exercisable as to 25% of the shares on January 31, 2018, and becomes exercisable as to 1/48th of the shares each full month thereafter. /s/ Jason W. Radford, Attorney-in-fact 2018-10-10